Dose-Dependent Association Between Use of Loop Diuretics and Mortality in Advanced Systolic Heart Failure

American Journal of Cardiology

Volumn 98, Issue 10, 2006, Pages 1416-1417

  Chuen, M Jennifer Ng Kam ^a   MacFadyen, Robert J ^a  

^a Birmingham ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT;

DEHYDRATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LETTER; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BUMETANIDE; CALIFORNIA; CREATININE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STROKE VOLUME; SULFONAMIDES; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33750507241     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.08.007     Document Type: Letter

References (11)

1. Eshaghian S., Horwich T.B., and Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97 (2006) 1759-1764
2. Neuberg G.W., Miller A.B., O'Connor C.M., Belkin R.N., Carson P.E., Cropp A.B., Frid D.J., Nye R.G., Pressler M.L., Wertheimer J.H., Packer M., and PRAISE Investigators. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
3. MacFadyen R.J., Gorski J.C., Brater D.C., and Struthers A.D. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol 57 (2003) 622-631
4. Brater D.C. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J 72 suppl (1994) S40-S43
5. Gottlieb S.S., Brater D.C., Thomas I., Havranek E., Bourge R., Godlman S., Dyer F., Gomez M., Bennett D., Ticho B., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
6. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., and Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
7. Ikram H., Chan W., Espiner E.A., and Nicholls M.G. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci 59 (1980) 443-447
8. MacFadyen R.J., Lee A., Morton J.J., Pringle S.D., and Struthers A.D. How often are angiotensin II and aldosterone concentration raised during chronic ACE inhibitor treatment in cardiac failure. Heart 82 (1999) 57-61
9. MacFadyen R.J., Barr C.S., and Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35 (1997) 30-34
10. Domanski M., Norman J., Pitt B., Haigney M., Hanlon S., and Peyster E. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 42 (2003) 705-708
11. Grinstead W.C., Francis M.J., Marks G.F., Tawa C.B., Zoghbi W.A., and Young J.B. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 73 (1994) 881-886